Epidemic

NCL Corporation Ltd. Announces Pricing of $790,000,000 of Senior Secured Notes

Retrieved on: 
Wednesday, October 11, 2023
Norwegian Cruise Line, Investment, Health, COVID-19, Public expenditure, Unemployment, Climate change, NYSE, NCLH, Note, Norwegian Cruise Line Holdings, NCL, Insurance, Travel, Safety, Stock dilution, Epidemic, Failure, Pandemic, Ship, Piracy, Environment, Growth, Maintenance, Person, Information technology, Annual report, SEC Rule 144A, Sale, Name, Security (finance), Bank, Risk management, Credit, Renewable energy, Tourism

The offering of the Notes is expected to close on October 18, 2023, subject to customary closing conditions as well as our entry into certain amendments to our senior secured credit facility.

Key Points: 
  • The offering of the Notes is expected to close on October 18, 2023, subject to customary closing conditions as well as our entry into certain amendments to our senior secured credit facility.
  • The Notes and the related guarantees will be secured by first-priority interests in, among other things and subject to certain agreed security principles, fourteen of our vessels that will also secure our senior secured credit facility and our 8.375% senior secured notes due 2028.
  • The Notes will be guaranteed by our subsidiaries that own the vessels that will secure the Notes.
  • This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

NCL Corporation Ltd. Announces Proposed Offering of Senior Secured Notes

Retrieved on: 
Wednesday, October 11, 2023
Norwegian Cruise Line, Investment, Health, COVID-19, Public expenditure, Unemployment, Climate change, NYSE, NCLH, Note, Norwegian Cruise Line Holdings, NCL, Insurance, Travel, Safety, Stock dilution, Epidemic, Failure, Pandemic, Ship, Piracy, Environment, Growth, Maintenance, Person, Information technology, Annual report, SEC Rule 144A, Sale, Name, Security (finance), Bank, Risk management, Credit, Renewable energy, Tourism

The Notes and the related guarantees will be secured by first-priority interests in, among other things and subject to certain agreed security principles, fourteen of our vessels that will also secure our senior secured credit facility and our 8.375% senior secured notes due 2028.

Key Points: 
  • The Notes and the related guarantees will be secured by first-priority interests in, among other things and subject to certain agreed security principles, fourteen of our vessels that will also secure our senior secured credit facility and our 8.375% senior secured notes due 2028.
  • The Notes will be guaranteed by our subsidiaries that own the vessels that will secure the Notes.
  • We intend to use the net proceeds from the Notes Offering, together with cash on hand, to repay the term loans outstanding under our senior secured credit facility, including to pay any accrued and unpaid interest thereon, as well as related premiums, fees and expenses.
  • The completion of the Notes Offering is conditioned on certain amendments to our senior secured credit facility.

Franklin Electric Schedules its Third Quarter 2023 Earnings Release and Conference Call

Retrieved on: 
Tuesday, October 10, 2023
Government, PIN, Weather, Franklin Electric, Epidemic, Pandemic, Movement, Marketing, Part, Exhibit, Housing, Water

It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).

Key Points: 
  • It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).
  • A replay of the conference call will be available from Tuesday, October 24, 2023, through 9:00 am ET on Tuesday, October 31, 2023, by visiting the listen-only webcast link above.
  • Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and fuel.
  • Recognized as a technical leader in its products and services, Franklin Electric serves customers around the world in residential, commercial, agricultural, industrial, municipal, and fueling applications.

Global and Regional Acute Care Syndromic Testing Market Analysis Report 2023: Respiratory Diseases and Bacterial Panels Dominate Acute Care Syndromic Testing Market in 2022 - Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023
Managed Care, Infectious Diseases, Health, Diagnosis, Disease, Incidence, Infection, Partnership, Data science, Bacteria, Target, Prescription, Treatment, Prevalence, PCR, Irritable bowel syndrome, Polymerase chain reaction, Mergers and acquisitions, Pandemic, Laboratory, Patient, FDA, Key, Abbott Laboratories, Growth, Region, Hospital, Microscopy, Physician, Pharmaceutical industry, Vaccine, Epidemic

The "Acute Care Syndromic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Target, Sample Type, End User and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Care Syndromic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Target, Sample Type, End User and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The acute care syndromic testing market has the potential to provide advanced healthcare solutions, with a focus on early detection and management of infectious diseases.
  • Respiratory Diseases Dominance: Respiratory panels hold the largest market share (56.29%) in 2022, ideal for distinguishing between viral and bacterial respiratory pathogens.
  • Hospitals as Key Users: Hospitals are the primary end users (42.53%) of syndromic testing, particularly in North America and Europe.

Global COVID-19 Competitive Landscape Report 2023: Comprehensive Insights on 400+ Companies and 500+ Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023
Infectious Diseases, Health, COVID-19, Shenzhen Stock Exchange, Respiratory failure, Acquisition, Report, Arcturus, Therapy, Coalition for Epidemic Preparedness Innovations, University, Safety, CEPI, Medication, AstraZeneca, Ageing, Siemens Healthineers, Vingroup, Developing country, Competitive landscape, Nanocovax, SARS-CoV-2, Epidemic, Coalition, Patient, Pharmaceutical industry, Vaccine

This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape.

Key Points: 
  • This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape.
  • The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends.
  • The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
  • Furthermore, the report delves into the development stages of emerging drugs, highlighting those in mid-stage and late-stage development, which are promising candidates for COVID-19 treatment.

IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Infectious Diseases, Clinical Trials, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Disease, Infection, NYSE, Global Public Health (journal), Research, Vaccine, IQV, Surge (drink), CEPI, Pandemic, G7, G20, Developing country, Epidemic, Low, Coalition for Epidemic Preparedness Innovations, Coalition, Patient, Pharmaceutical industry, IQVIA

IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.

Key Points: 
  • IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.
  • In conjunction with national and regional collaborators, CEPI and IQVIA will aim to enhance the world’s preparedness to rapidly conduct life-saving clinical research for vaccines and other biological countermeasures against emerging infectious diseases.
  • This clinical research preparedness has been identified as a key enabler of the 100 Days Mission : a goal spearheaded by CEPI, and backed by the G7 and G20, which aims to accelerate the time taken to develop safe, effective, globally accessible vaccines against emerging disease outbreaks to within 100 days.
  • IQVIA’s collaboration with CEPI will support the 100 Days Mission in delivering transformative healthcare worldwide.

AngloGold Ashanti plc Provides Corporate Restructuring Update

Retrieved on: 
Monday, October 9, 2023
Mining, Minerals, Natural Resources, Ghana Stock Exchange, Annual report, COVID-19, NYSE, Government, United Kingdom, JSE Limited, AGA, AngloGold Ashanti, F-4, FPI, Form 6-K, Epidemic, Pandemic, Form, Form 10-K, Accident, JSE, Risk, Security (finance)

AngloGold Ashanti plc (“AGA”) has completed a corporate restructuring resulting in a corporate domicile in the United Kingdom, and a change of its primary listing from the Johannesburg Stock Exchange (“JSE”) to the New York Stock Exchange (“NYSE”).

Key Points: 
  • AngloGold Ashanti plc (“AGA”) has completed a corporate restructuring resulting in a corporate domicile in the United Kingdom, and a change of its primary listing from the Johannesburg Stock Exchange (“JSE”) to the New York Stock Exchange (“NYSE”).
  • These tax payments have now been determined at about $286m, following the successful conclusion of the corporate restructuring transaction.
  • Certain statements contained in this document, other than statements of historical fact, are forward-looking statements regarding AngloGold Ashanti plc’s (“AngloGold Ashanti”) financial reports, operations, economic performance and financial condition.
  • All subsequent written or oral forward-looking statements attributable to AngloGold Ashanti or any person acting on its behalf are qualified by the cautionary statements herein.

Concentric by Ginkgo to Support CDC-Funded Consortium to Develop New AI-Based Technologies for Epidemic Forecasting

Retrieved on: 
Thursday, October 5, 2023
College of Science (Northeastern University), Hospital, Los Alamos National Laboratory, NYSE, Forecasting, Intelligence, Centers for Disease Control and Prevention, Boston University, Government, DNA, Concentric objects, Organization, CDC, Infection, Preventive healthcare, Fred Hutchinson Cancer Research Center, University, Epidemic, Indiana University, Ginkgo, San Diego, Vaccine, Northeastern University, Points of the compass

BOSTON, Oct. 5, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its biosecurity and public health unit, Concentric by Ginkgo, will partner with Northeastern University, which has received a grant from the Centers of Disease Control and Prevention over the next five years to head an innovation center led by a consortium of organizations designed to help the United States to detect and prepare for the next outbreak of infectious disease.

Key Points: 
  • With the CDC's support, Northeastern will lead a nationwide consortium to develop systems to prepare local communities and hospitals across various geographic regions—including rural areas—for outbreaks, according to the university's announcement .
  • Concentric will contribute its unique blend of computational epidemiology, risk modeling, and social science expertise, supported by an extensive laboratory network.
  • Concentric will also support development of new AI-based early warning systems capable of synthesizing multiple indicators to anticipate sharp changes of disease activity.
  • "We are thrilled to partner with CDC, Northeastern University, and the EPISTORM consortium to develop new technologies for early warning and epidemic forecasting," said Nita Madhav, Head of Epidemiology and Global Risk Analytics at Concentric by Ginkgo.

HDT Bio Receives $1 Million Award from BLUE KNIGHT™ Resident QuickFire Challenge in Support of Project NextGen

Retrieved on: 
Wednesday, October 4, 2023
Infection, ASPR, BLUE, Biomedical Advanced Research and Development Authority, Nasal cavity, Office of Inspector General, U.S. Department of Health and Human Services, HHS, SARS-CoV-2, Cancer, Anglo-Scandinavian, RNA, Epidemic, Development, Administration, Administration for Strategic Preparedness and Response, BARDA, Disease, Vaccine

Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate

Key Points: 
  • Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate
    SEATTLE, Oct. 4, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that it has received a $1 million award from the BLUE KNIGHT™ Resident QuickFire Challenge.
  • BLUE KNIGHT is a joint initiative between the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), and Johnson & Johnson Innovation – JLABS (JLABS).
  • The award will be used to support further development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal small RIG-I Agonist RNA antiviral candidate to prevent infection and transmission of SARS-CoV-2.
  • "We are honored to be recognized as an awardee of the BLUE KNIGHT™ Resident QuickFire Challenge and welcome the opportunity to collaborate together with BARDA to increase preparedness against new and ongoing epidemics.

World Business Forum New York Selects Doctors Without Borders as Social Impact Partner, Announces Spotlight on Sustainability

Retrieved on: 
Tuesday, October 3, 2023
GS1, IBM, Responsibility, Senior, Médecins Sans Frontières, Lincoln Center, Innovation, Optimism, World Business Forum, Creativity, VF Corporation, Epidemic, WBF, Knowledge, Global Sustainable Investment Alliance, Border, AI, Partnership, GS1 US, Pharmaceutical industry, Management

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- WOBI, a major provider of leadership content for the business community, has named Doctors Without Borders as its Social Impact Partner for the upcoming 20th anniversary World Business Forum New York .

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- WOBI, a major provider of leadership content for the business community, has named Doctors Without Borders as its Social Impact Partner for the upcoming 20th anniversary World Business Forum New York .
  • PURPOSE is the principal theme of this year's World Business Forum, being held at Lincoln Center on November 15-16.
  • "World Business Forum New York attracts leaders from more than 40 countries each year – as we celebrate the 20th anniversary of the World Business Forum we are excited to showcase an organization that has a global impact," said Chris Stanley, WOBI's Managing Director.
  • "We're honored to have Doctors Without Borders as our Social Impact Partner, serving as an example of a world-changing organization with purpose as its core mission."